Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 add-on to birch pollen subcutaneous immunotherapy in allergic rhinitis
2018-001339-33Phase 2Completed
- Sponsor
- Amsterdam UMC
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and birch pollen allergy comparing SCIT + Zemplar with SCIT + placebo (2 arms). Started Jun 2018; status: completed.
02
Drugs
paricalcitol
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)birch pollen allergy
Beyond the preview
Go deeper on 2018-001339-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001339-33.